What the New Vitamin B12 Therapy Means for Japanese ALS Patients (opens in new tab)
The focus on "moderate progressors" reflects trial design considerations—patients who decline too slowly make it difficult to measure drug
Read the original articleThe focus on "moderate progressors" reflects trial design considerations—patients who decline too slowly make it difficult to measure drug
Read the original article